Related Experiment Video
Updated: Jan 25, 2026

Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices
Published on: September 8, 2023
The Experience of the Derivo® Embolisation Device in Intracranial Aneurysms
Ergun Daglioglu1, Ilkay Akmangit, Vedat Acik
1Ankara Numune Training and Research Hospital, Department of Neurosurgery, Ankara, Turkey.
Insights
The Derivo® embolisation device (DED) safely and effectively treats brain aneurysms, showing good long-term outcomes. This new flow diverter achieved high occlusion rates with low complication risks in patients, including those with subarachnoid hemorrhage.
Area of Science:
- Neurosurgery
- Interventional Neuroradiology
- Biomedical Engineering
Background:
- Cerebrovascular aneurysms pose significant risks, including subarachnoid hemorrhage.
- Flow diverters represent a new-generation treatment for complex aneurysms.
- The Derivo® embolisation device (DED) is a novel flow diverter for aneurysm treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of the DED for treating cerebrovascular aneurysms.
- To assess the long-term clinical outcomes of DED treatment.
- To determine the occlusion rates and complication profile of DED.
Main Methods:
- 146 patients with 182 aneurysms were treated using the DED.
- The study included patients with acute subarachnoid hemorrhage and various aneurysm locations.
- Aneurysm occlusion was assessed at a mean follow-up of 7.02 months.
Main Results:
- The DED demonstrated a complete aneurysm occlusion rate of 78.7%.
- The device was associated with a low mortality rate of 2.7% and permanent morbidity of 3.4%.
- Favorable outcomes were observed even in patients presenting with subarachnoid hemorrhage.
Conclusions:
- The DED is a safe and effective new-generation flow diverter for cerebrovascular aneurysms.
- The device offers excellent opening and navigational properties.
- DED treatment resulted in optimal morbidity and mortality rates, supporting its use in complex cases.
Aim:
To investigate the safety and efficacy of Derivo® embolisation device (DED), a new-generation flow diverter designed to treat cerebrovascular aneurysms, and its long-term clinical outcomes.
Material And Methods:
In total, 146 patients with 182 aneurysms were treated with DED. The mean age of the participants was 51.5 years; among them, 46 (31.5%) presented with acute subarachnoid haemorrhage. The mean aneurysm size was 8.3 mm, and 12 aneurysms were involved the vertebrobasilar system. Ophthalmic aneurysms account for most internal carotid artery (ICA) aneurysms.
Results:
The Glasgow Coma Scale (GCS) score of 12 patients was < 15. DED was associated with a mortality rate of 2.7% and permanent morbidity rate of 3.4%, and a complete aneurysm occlusion rate was achieved in 78.7% of cases after 7.02 months.
Conclusion:
The DED device is a new-generation flow diverter with excellent opening behaviour and navigational benefits. Our results indicated a safe aneurysm occlusion with optimum morbidity and mortality values despite the fact that almost one-third of the patients presented with subarachnoid haemorrhage.
Related Concept Videos
Aneurysm I: Introduction
What is an Experiment?
Aneurysm IV: Nursing Management
Thomson's e/m Experiment
A particle with charge q, speed v, and mass m enters an area from the top, where the magnetic and electric fields are perpendicular both to the particle's motion and to one another. The magnetic...
Aneurysm III: Interprofessional Care
Controls in Experiments

